Exelixis (EXEL) PT Bumped to $8 at Piper Jaffray, Remains Sidelined

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Exelixis (EXEL) PT Bumped to $8 at Piper Jaffray, Remains Sidelined

Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update

August 3, 2016 4:08 PM EDT

- Launch of CABOMETYX Results in Cabozantinib Franchise Sales of $31.6 Million -

- Conference Call and Webcast Today at 5:00 PM Eastern Time -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2016 and provided an update on progress toward delivering upon its key 2016 corporate objectives, as well as commercial and clinical development milestones.

Exelixis is focused on executing the U.S. launch of CABOMETYX (cabozantinib) tablets as a treatment for patients with advanced... More